EyeGate Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of EyeGate Pharmaceuticals generated cash of -$7,317,169, which is more than the previous year. Cash used in financing activities reached the amount of $4,997,503 last year. Net change in cash is therefore -$2,591,035.
Cash Flow
| 2012 | -5.22M | 0 | -75.40K |
|---|---|---|---|
| 2013 | -2.95M | 0 | 1.46M |
| 2014 | -950.61K | 0 | 613.27K |
| 2015 | -4.45M | -20K | 12.61M |
| 2016 | -8.41M | 149.74K | 3.49M |
| 2017 | -6.46M | -36.99K | 10.67M |
| 2018 | -10.84M | -270K | 11.30M |
| 2019 | -8.15M | 0 | 3.92M |
| 2020 | -7.31M | -244.43K | 4.99M |
EYEG Cash Flow Statement (2012 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.82M | 8.04M | 7.85M | 3.68M | 8.39M | 167.00K | 501.17K | 1.97M | 7.27M |
Operating activities | |||||||||
Net income | -8.09M | -7.09M | -10.81M | -13.21M | -13.34M | -8.39M | -1.77M | -3.87M | -6.03M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 33.39K | 213.93K | 38.48K | 19.28K | 5.18K | 1.25K | 1.72K | 5.45K | 9.09K |
Stock-based compensation expense | 723.85K | 852.23K | 875.28K | 870.30K | 510.99K | 1.22M | 26.81K | 184.03K | 396.37K |
| Deferred income tax benefit | 723.85K | 852.23K | 875.28K | 870.30K | 510.99K | 1.22M | 26.81K | 184.03K | 396.37K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -18.95K | 0 | 0 | 0 | 0 | -907.5K | 0 | 0 | 0 |
Inventories | -3.02M | 0 | 0 | 0 | 0 | 5.86M | 0 | 0 | 0 |
Accounts payable | 136.69K | 146.63K | -642.43K | -706.03K | 712.79K | -148.25K | 552.25K | -96.05K | 26.18K |
Cash generated by operating activities | -7.31M | -8.15M | -10.84M | -6.46M | -8.41M | -4.45M | -950.61K | -2.95M | -5.22M |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -133.79K | 0 | -270K | -36.99K | -11K | 0 | 0 | 0 | 0 |
Acquisitions Net | -110.64K | 0 | 0 | 0 | 185.74K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -244.43K | 0 | -270K | -36.99K | 149.74K | -20K | 0 | 0 | 0 |
Financing activities | |||||||||
Common Stock Issued | 5M | 1.77M | 10.10M | 11.92M | 3.76M | 14.10M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 4.99M | 3.92M | 11.30M | 10.67M | 3.49M | 12.61M | 613.27K | 1.46M | -75.40K |
Net Change In Cash | -2.59M | -4.22M | 198.20K | 4.17M | -4.75M | 8.22M | -334.17K | -1.47M | -5.30M |
Cash at end of period | 1.23M | 3.82M | 8.04M | 7.85M | 3.63M | 8.39M | 167.00K | 501.17K | 1.97M |
| Data source | Data source | Data source | Data source | Data source | Data source |